Candel therapeutics announces nature publication showing extended survival associated with immune activation in patients with recurrent high-grade glioma treated with can-3110

Needham, mass., oct. 18, 2023 (globe newswire) -- candel therapeutics, inc. (the company or candel) (nasdaq: cadl), a clinical stage biopharmaceutical company focused on developing viral immunotherapies to help patients fight cancer, today announced that nature published results from the ongoing first-in-human phase 1 investigator-sponsored clinical trial of can-3110, a first-in-class, replication-competent herpes simplex virus-1 (hsv-1) oncolytic viral immunotherapy candidate, in patients with recurrent high-grade glioma (hgg), of which 86.7% were glioblastoma, that had returned after standard of care (soc) treatment.
CADL Ratings Summary
CADL Quant Ranking